See more : Mobilicom Ltd (MOB) Income Statement Analysis – Financial Results
Complete financial analysis of Santhera Pharmaceuticals Holding AG (SPHDF) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Santhera Pharmaceuticals Holding AG, a leading company in the Biotechnology industry within the Healthcare sector.
- China National Culture Group Limited (0745.HK) Income Statement Analysis – Financial Results
- Malmbergs Elektriska AB (publ) (MEAB-B.ST) Income Statement Analysis – Financial Results
- Southwest Gas Holdings, Inc. (SWX) Income Statement Analysis – Financial Results
- Boart Longyear Group Ltd. (BLYFF) Income Statement Analysis – Financial Results
- Cowen Inc. (COWN) Income Statement Analysis – Financial Results
Santhera Pharmaceuticals Holding AG (SPHDF)
About Santhera Pharmaceuticals Holding AG
Santhera Pharmaceuticals Holding AG, a specialty pharmaceutical company, together with its subsidiaries, develops and commercializes medicines for rare neuromuscular and pulmonary diseases with high unmet medical need in the European Union and internationally. The company's lead pipeline candidate includes vamorolone, which is being developed as treatments for Duchenne muscular dystrophy (DMD). Its clinical stage pipeline also comprises lonodelestat (POL6014) to treat cystic fibrosis and other neutrophilic pulmonary diseases, as well as omigapil that treats congenital muscular dystrophies. The company also out-licenses outside North America and France rights to its approved product, Raxone (idebenone), for the treatment of Leber's hereditary optic neuropathy. Santhera Pharmaceuticals Holding AG was founded in 2004 and is headquartered in Pratteln, Switzerland.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 122.95M | 8.08M | -1.75M | 16.98M | 77.84M | 32.11M | 23.54M | 18.73M | 4.32M |
| Cost of Revenue | 3.85M | 4.54M | 4.88M | 16.44M | 7.42M | 5.48M | 4.56M | 4.04M | 1.48M |
| Gross Profit | 119.11M | 3.54M | -6.63M | 541.89K | 70.42M | 26.63M | 18.98M | 14.68M | 2.84M |
| Gross Profit Ratio | 96.87% | 43.80% | 379.06% | 3.19% | 90.47% | 82.93% | 80.62% | 78.42% | 65.73% |
| Research & Development | 18.67M | 33.02M | 32.57M | 38.72M | 42.59M | 38.79M | 27.26M | 17.39M | 10.44M |
| General & Administrative | 21.18M | 14.57M | 12.73M | 12.44M | 19.18M | 0.00 | 0.00 | 0.00 | 0.00 |
| Selling & Marketing | 9.78M | 10.86M | 9.33M | 11.47M | 20.10M | 0.00 | 0.00 | 0.00 | 0.00 |
| SG&A | 30.97M | 20.12M | 23.43M | 22.42M | 34.64M | 40.12M | 43.71M | 30.14M | 16.47M |
| Other Expenses | -12.38M | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 946.05K |
| Operating Expenses | 37.26M | 53.14M | 56.00M | 61.14M | 77.24M | 78.91M | 70.97M | 47.53M | 25.97M |
| Cost & Expenses | 41.10M | 57.68M | 60.88M | 77.58M | 84.65M | 84.39M | 75.53M | 51.57M | 27.45M |
| Interest Income | 404.00K | 0.00 | 1.00K | 3.00K | 8.00K | 94.34K | 279.12K | 4.92K | 2.00K |
| Interest Expense | 21.31M | 21.84M | 16.42M | 6.89M | 6.08M | 4.57M | 3.94M | 15.00K | 11.00K |
| Depreciation & Amortization | 3.61M | 3.94M | 4.08M | 8.07M | 4.93M | 3.80M | 3.47M | 3.21M | 1.12M |
| EBITDA | 79.18M | -45.66M | -37.89M | -52.52M | -7.79M | -46.28M | -45.20M | -29.63M | 4.05M |
| EBITDA Ratio | 64.40% | -564.95% | 3,348.59% | -309.36% | -2.42% | -150.97% | -206.07% | -158.24% | -509.93% |
| Operating Income | 81.85M | -49.60M | -62.62M | -60.60M | -6.81M | -52.28M | -51.99M | -32.84M | -23.13M |
| Operating Income Ratio | 66.57% | -613.77% | 3,582.07% | -356.91% | -8.75% | -162.79% | -220.81% | -175.38% | -535.89% |
| Total Other Income/Expenses | -27.03M | -24.39M | 2.65M | -15.71M | -7.60M | -2.36M | -631.09K | 183.99K | 26.06M |
| Income Before Tax | 54.82M | -76.36M | -59.98M | -76.31M | -19.00M | -54.64M | -52.62M | -32.66M | 2.93M |
| Income Before Tax Ratio | 44.59% | -944.95% | 3,430.53% | -449.47% | -24.40% | -170.15% | -223.49% | -174.40% | 67.90% |
| Income Tax Expense | 38.00K | 497.44K | 886.74K | 229.65K | 597.92K | 326.64K | 263.72K | 2.19M | -3.01M |
| Net Income | 65.07M | -76.86M | -60.86M | -76.54M | -19.59M | -54.97M | -52.88M | -34.85M | 5.94M |
| Net Income Ratio | 52.92% | -951.10% | 3,481.25% | -450.82% | -25.17% | -171.17% | -224.61% | -186.07% | 137.68% |
| EPS | 6.16 | -12.62 | -17.81 | -57.48 | -17.83 | -79.76 | -84.34 | -55.54 | 11.12 |
| EPS Diluted | 5.96 | -12.62 | -17.81 | -57.48 | -17.83 | -79.76 | -84.34 | -55.54 | 10.84 |
| Weighted Avg Shares Out | 10.58M | 6.09M | 3.42M | 1.33M | 1.10M | 689.16K | 626.98K | 627.35K | 534.31K |
| Weighted Avg Shares Out (Dil) | 10.92M | 6.09M | 3.42M | 1.33M | 1.10M | 689.16K | 626.98K | 627.35K | 548.35K |
Source: https://incomestatements.info
Category: Stock Reports